somapacitan

02/01/2023 - "In post hoc-defined analyses, we compared the effects of somapacitan with daily growth hormone (GH) and placebo on fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR) and beta-cell function (HOMA-β) in patients with AGHD across a unique data set from three phase 3 randomized controlled trials (REAL 1, REAL 2 and REAL Japan). "

11/25/2022 - "Low proportions of injection-site reactions were reported for somapacitan (5.3%) and daily GH (5.9%). "
01/01/2020 - "Somapacitan was well tolerated, with similar adverse events (including injection-site reactions) compared with daily GH. "
10/01/2017 - "Four mild transient injection site reactions were reported in three of 24 children treated with somapacitan. "
05/01/2018 - "More than 1500 somapacitan injections were administered and no clinically significant injection site reactions were reported. "
05/01/2018 - "Outcome measures were adverse events (AEs), including injection site reactions; occurrence of anti-somapacitan/anti-GH antibodies and change in treatment satisfaction, assessed using the Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9). "

01/01/2021 - "After its administration as a subcutaneous injection, the action of somapacitan can be affected by kidney or liver disease. "
01/01/2021 - "Our results indicate that patients with growth hormone deficiency and kidney or liver disease may need different doses of somapacitan than people with healthy kidneys and/or liver. "

02/01/2023 - "No new cases of diabetes mellitus were reported with somapacitan. "

01/01/2017 - "Multiple once weekly dosing of somapacitan in hypophysectomised rats induced a step-wise increase in body weight with an initial linear phase the first 3-4days in each dosing interval (p<0.001). "
01/01/2017 - "Somapacitan induced a dose-dependent increase in body weight and IGF-I levels in hypophysectomised rats. "